Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | PKM | P14618 | 6/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TDO2 | P48775 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKLR | P30613 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | GPR183 | P32249 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1180894 | 0.98 | MAPT (0.67) | MAPTPKMALDH1A1TDO2MEN1 | |
| Benzenesulfonamide SCHEMBL5085618 | 0.87 | PKM (0.68) | MAPTPKMALDH1A1TDO2MEN1 | |
| SCHEMBL1711115 | 0.86 | PKM (0.85) | MAPTPKMALDH1A1MEN1KMT2A | |
| SCHEMBL423283 | 0.82 | MAPT (0.74) | MAPTPKMALDH1A1MEN1KMT2A | |
| SCHEMBL3236916 | 0.82 | MAPT (0.80) | MAPTPKMALDH1A1MEN1KMT2A | |
| SCHEMBL8724931 | 0.81 | MAPT (0.69) | MAPTPKMALDH1A1TDO2POLB | |
| SCHEMBL651924 | 0.81 | MAPT (0.69) | MAPTPKMALDH1A1MEN1KMT2A | |
| SCHEMBL16442322 | 0.81 | MAPT (0.69) | MAPTPKMALDH1A1L3MBTL1POLB | |
| SCHEMBL5955341 | 0.81 | MAPT (0.69) | MAPTPKMALDH1A1MEN1KMT2A | |
| SCHEMBL11510345 | 0.81 | MAPT (0.69) | MAPTPKMALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720528-A | Oxadiazole sulfonamide compound containing pyrazole structure, and preparation method and application thereof | 贵州大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-117586179-A | GPR183 antagonist and synthetic method and application thereof | 中国人民解放军海军特色医学中心 | 2024-02-23 | — | — | CN | disclosed |
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-112209910-B | Myricetin derivative containing sulfonyl piperazine, preparation method and application | 贵州大学 | 2023-10-17 | — | — | CN | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116606292-A | Pyrido [1,2-a ] pyrimidinone derivatives containing sulfonamide unit, preparation method and application thereof | 贵州大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-114634465-B | Pentadienone derivative containing sulfonyl piperazine as well as preparation method and application thereof | 贵州大学 | 2023-05-30 | — | — | CN | disclosed |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| EP-0702013-A2 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1996-03-20 | — | — | EP | disclosed |
| US-5476857-A | Imidazopyridines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-12-19 | — | — | US | disclosed |
| US-5438063-A | Hypotensive agents, cardiac insufficiency, increased intraocular pressure, and CNS disorders | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-08-01 | — | — | US | disclosed |
| EP-0657452-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0657454-A1 | Imidazopyridazines being angiotensin II antagonists | MERCK PATENT GmbH (DE) | 1995-06-14 | — | — | EP | disclosed |
| EP-0628556-A1 | Imidazopyridines | MERCK PATENT GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0574846-A2 | Imidazopyridines as angiotensin II antagonistes | MERCK PATENT GmbH (DE) | 1993-12-22 | — | — | EP | disclosed |
| EP-0203743-B1 | OXOTHIAZOLIDINE COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-06 | — | — | EP | disclosed |
| US-4764514-A | COGNITIONACTIVATORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-08-16 | — | — | US | disclosed |
| EP-0203743-A1 | Oxothiazolidine compound | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | MAPT 619/4885PKM 688/4885ALDH1A1 1096/4885 |
| US-20230082430-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | CRBN, IKZF1, IKZF3 | MAPT 1742/4885PKM 3041/4885ALDH1A1 3827/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | MAPT 619/4885PKM 688/4885ALDH1A1 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.